The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
42 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $39,027,620 in first-year total cost, median $961,452.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-E (M1)]42
Most frequent institutions
- DANA-FARBER CANCER INST6
- SLOAN-KETTERING INST CAN RESEARCH5
- COLUMBIA UNIVERSITY HEALTH SCIENCES2
- ST. JUDE CHILDREN'S RESEARCH HOSPITAL2
- UT SOUTHWESTERN MEDICAL CENTER2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes2R35CA220500-08A1 | MARIS, JOHN M | CHILDREN'S HOSP OF PHILADELPHIA, PA | $1,068,000 | ZCA1 |
| 2025 | Overcoming Resistance to Targeted Therapy in Breast Cancer1R35CA305347-01 | CHANDARLAPATY, SARAT | SLOAN-KETTERING INST CAN RESEARCH, NY | $1,056,000 | ZCA1 |
| 2025 | Understanding and Targeting Aberrant RNA Splicing in Leukemia1R35CA304457-01 | ABDEL-WAHAB, OMAR | SLOAN-KETTERING INST CAN RESEARCH, NY | $1,034,176 | ZCA1 |
| 2025 | Targeting DNA Repair for Cancer Therapy.2R35CA197574-08A1 | GLAZER, PETER M | YALE UNIVERSITY, CT | $1,005,000 | ZCA1 |
| 2025 | Understanding and Exploiting Loss of Y in Cancer1R35CA294022-01A1 | THEODORESCU, DAN | UNIVERSITY OF ARIZONA, AZ | $930,500 | ZCA1 |
| 2025 | Chemical Proteomic Platforms for Radically Expanding Cancer Druggability2R35CA231991-08 | CRAVATT, BENJAMIN F | SCRIPPS RESEARCH INSTITUTE, THE, CA | $916,320 | ZCA1 |
| 2025 | Effect of tumor editing on antitumor immunity1R35CA305089-01 | LIEBERMAN, JUDY | BOSTON CHILDREN'S HOSPITAL, MA | $901,205 | ZCA1 |
| 2025 | Human natural killer cells: Advancing biology and clinical applications2R35CA210087-08A1 | CALIGIURI, MICHAEL A | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $886,438 | ZCA1 |
| 2025 | New approaches to targeting cell cycle proteins for cancer treatment1R35CA305086-01 | SICINSKI, PETER | DANA-FARBER CANCER INST, MA | $855,249 | ZCA1 |
| 2025 | Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy1R35CA294015-01A1 | BOUSSIOTIS, VASSILIKI A | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $846,982 | ZCA1 |
| 2025 | Systems genetics analysis of tumor evolution in the mouse2R35CA210018-08A1 | BALMAIN, ALLAN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $816,707 | ZCA1 |
| 2025 | Mesoscale and Nanoscale Technologies Integrated by Structures for DNA Repair Complexes (MANTIS-DRC)2R35CA220430-08 | TAINER, JOHN A. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $814,230 | ZCA1 |
| 2025 | Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies2R35CA210084-08A1 | DIPERSIO, JOHN F. | WASHINGTON UNIVERSITY, MO | $713,138 | ZCA1 |
| 2024 | Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer2R35CA220538-08 | SHAW, REUBEN | SALK INSTITUTE FOR BIOLOGICAL STUDIES, CA | $1,140,000 | ZCA1 |
| 2024 | The TET-DNMT-ASXL1-OGT axis: relevance to clonal hematopoiesis, heterochromatin integrity and cancer2R35CA210043-08A1 | RAO, ANJANA | LA JOLLA INSTITUTE FOR IMMUNOLOGY, CA | $1,098,000 | ZCA1 |
| 2024 | Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation2R35CA197570-08 | COFFEY, ROBERT J. | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $1,062,441 | ZCA1 |
| 2024 | Role of Phosphoinositides and Protein Kinases in the control of Cancer Metabolism2R35CA197588-08 | CANTLEY, LEWIS C. | DANA-FARBER CANCER INST, MA | $1,052,496 | ZCA1 |
| 2024 | Precision Engineering of STING-DC Immunity to Overcome Tumor Immune Evasion1R35CA294010-01 | GAO, JINMING | UT SOUTHWESTERN MEDICAL CENTER, TX | $984,000 | ZCA1 |
| 2024 | MECHANISMS OF REGULATED CELL DEATH2R35CA231620-08 | GREEN, DOUGLAS R. | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $955,876 | ZCA1 |
| 2024 | Targeting Glioblastoma Stem Cells1R35CA283998-01A1 | RICH, JEREMY N | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $954,000 | ZCA1 |
| 2024 | Mechanisms Driving the Rapid Evolution of Cancer Genomes1R35CA293978-01 | PELLMAN, DAVID S | DANA-FARBER CANCER INST, MA | $942,442 | ZCA1 |
| 2024 | Defining Drivers of HPV-associated Carcinogenesis2R35CA210807-08 | LAMBERT, PAUL F. | UNIVERSITY OF WISCONSIN-MADISON, WI | $933,000 | ZCA1 |
| 2024 | Next Generation Immunotherapies for Pediatric Cancers1R35CA283888-01A1 | MACKALL, CRYSTAL | STANFORD UNIVERSITY, CA | $931,841 | ZCA1 |
| 2024 | Emerging Strategies for Therapy of Metastatic Brain Cancer1R35CA283939-01A1 | LESNIAK, MACIEJ S | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $895,779 | ZCA1 |
| 2024 | Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance1R35CA283706-01A1 | RONAI, ZEEV A. | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $343,564 | ZCA1 |
| 2023 | Establishing and Interpreting Abnormal DNA Methylation in Cancer2R35CA209859-08 | JONES, PETER A | VAN ANDEL RESEARCH INSTITUTE, MI | $1,146,514 | ZCA1 |
| 2023 | Translating genomic discoveries to improved outcomes for high risk acute leukemia2R35CA197695-08 | MULLIGHAN, CHARLES G. | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $1,092,000 | ZCA1 |
| 2023 | Targeting Pediatric Cancer Vulnerabilities1R35CA283977-01 | STEGMAIER, KIMBERLY | DANA-FARBER CANCER INST, MA | $1,066,178 | ZCA1 |
| 2023 | Synergistic role of signaling and epigenetics in leukemic transformation2R35CA197594-08 | LEVINE, ROSS L | SLOAN-KETTERING INST CAN RESEARCH, NY | $1,062,000 | ZCA1 |
| 2023 | Integrating targeted therapy and immunotherapy to break through cancer2R35CA210057-08 | ZHAO, JEAN | DANA-FARBER CANCER INST, MA | $1,027,633 | ZCA1 |
| 2023 | Genome instability in cancer: telomeres and DNA repair2R35CA210036-08 | DE LANGE, TITIA | ROCKEFELLER UNIVERSITY, NY | $1,007,774 | ZCA1 |
| 2023 | The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations2R35CA210068-08 | KAELIN, WILLIAM G. | DANA-FARBER CANCER INST, MA | $997,800 | ZCA1 |
| 2023 | From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma2R35CA210105-08 | DALLA-FAVERA, RICCARDO | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $987,000 | ZCA1 |
| 2023 | The role of stem cells and the microenvironment in gastrointestinal cancers2R35CA210088-08 | WANG, TIMOTHY CRAGIN | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $987,000 | ZCA1 |
| 2023 | Social Determinants of Health as Transducers of Cellular Aging: A New Multi-level Paradigm to Reduce Survivorship Disparities at the Intersection of Cancer and Aging1R35CA283926-01 | MANDELBLATT, JEANNE | GEORGETOWN UNIVERSITY, DC | $980,446 | ZCA1 |
| 2023 | Overcoming resistance to anti-PD1 immunotherapy2R35CA210098-08 | GAJEWSKI, THOMAS F | UNIVERSITY OF CHICAGO, IL | $970,168 | ZCA1 |
| 2023 | Human metabolic variation as a window into cancer initiation and progression2R35CA220449-07 | DEBERARDINIS, RALPH J | UT SOUTHWESTERN MEDICAL CENTER, TX | $967,027 | ZCA1 |
| 2023 | Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors1R35CA283892-01 | MILLER, JEFFREY S. | UNIVERSITY OF MINNESOTA, MN | $928,524 | ZCA1 |
| 2023 | Exploring the Role of Nitrogen Metabolism in Cancer1R35CA283988-01 | THOMPSON, CRAIG B | SLOAN-KETTERING INST CAN RESEARCH, NY | $926,340 | ZCA1 |
| 2023 | Metabolic Influences on Complex Tumor Neighborhoods2R35CA220483-08 | SIMON, M. CELESTE | UNIVERSITY OF PENNSYLVANIA, PA | $925,000 | ZCA1 |
| 2023 | Developing a Suite of Targeted Anticancer Drugs1R35CA283859-01 | HERGENROTHER, PAUL | UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, IL | $515,200 | ZCA1 |
| 2023 | The role of the intestinal microbiome in cancer immunotherapy1R35CA284024-01 | VAN DEN BRINK, MARCEL R M | SLOAN-KETTERING INST CAN RESEARCH, NY | $303,632 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.